One thousand consecutive primary liver transplants under tacrolimus immunosuppression: A 17- to 20-year longitudinal follow-up

Transplantation

Volumn 91, Issue 9, 2011, Pages 1025-1030

  Jain, Ashokkumar ^a   Singhal, Ashish ^a   Fontes, Paulo ^b   Mazariegos, George ^b   Devera, Michael E ^b   Cacciarelli, Thomas ^b   Lopez, Roberto C ^b   Sindhi, Rakesh ^b   Humar, Abhi ^b   Marsh, J Wallis ^b  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Calcineurin inhibitor; Nephrotoxicity; Rejection; Survival; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADJUVANT THERAPY; ADULT; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHILD; DIABETES MELLITUS; DIALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEPATIC ARTERY THROMBOSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MORTALITY; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFEATIVE DISORDER; PRIORITY JOURNAL; RECURRENT DISEASE; RETRANSPLANTATION; SKIN CANCER; SURVIVAL RATE;

EID: 85027942257     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182129215     Document Type: Article

References (66)

1. Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000.
2. Todo S, Fung JJ, Starzl TE, et al. Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990; 212: 295.
3. Fung JJ, Todo S, Tzakis A, et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: Benefits and pitfalls. Transplant Proc 1991; 23: 14.
4. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy-A clinicopathologic study of 96 patients. Transplantation 1992; 53: 1056.
5. Fung JJ, Eliasziw M, Todo S, et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183: 117.
6. Busuttil RW, Holt CD. Tacrolimus is superior to cyclosporine in liver transplantation. Transplant Proc 1998; 30: 2174.
7. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994;344: 423-428
8. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
9. Todo S, Fung JJ, Starzl TE, et al. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg 1994; 220: 297.
10. Starzl TE, Donner A, Eliasziw M, et al. Randomized trialomania? The multicenter liver transplant trials of tacrolimus. Lancet 1995; 346: 1346.
11. Sher LS, Cosenza CA, Michel J, et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: A report of the U.S. Multicenter Liver Study Group. Transplantation 1997; 64: 258.
12. Reyes J, Jain AB, Mazariegos G, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000; 69: 2573.
13. Jain A, Mazariegos G, Kashyap R, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation 2000; 70: 617.
14. Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK 506. Transplant Proc 1991; 23: 3105.
15. Kang Y, Mazer MA, DeWolf AM, et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. Transplant Proc 1990; 22: 21.
16. McCauley J, Fung JJ, Todo S, et al. Changes in renal function after liver transplantation under FK 506. Transplant Proc 1991; 23: 3143.
17. Mieles L, Todo S, Fung JJ, et al. Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc 1990; 22: 41
18. Reyes J, Gayowski T, Fung J, et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. Transplantation 1990; 50: 1043.
19. Ricordi C, Zeng YJ, Alejandro R, et al. In vivo effect of FK506 on human pancreatic islets. Transplantation 1991; 52: 519.
20. Singh N, Gayowski T, Wagener M, et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. Transplantation 1994; 58: 774.
21. Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc 1991; 23: 3175.
22. Wiesner RH. Long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group. Transplantation 1998; 66: 493.
23. McKenna GJ, Sanchez EQ, Chinnakotla S, et al. The Baylor Regional Transplant Institute: Review of a twenty-year experience. Clin Transpl 2004: 221.
24. Busuttil RW, Farmer DG, Yersiz H, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: A single-center experience. Ann Surg 2005; 241: 905.
25. Abbasoglu O, Levy MF, Brkic BB, et al. Ten years of liver transplantation: An evolving understanding of late graft loss. Transplantation 1997; 64: 1801.
26. Soltys KA, Mazariegos GV, Squires RH, et al. Late graft loss or death in pediatric liver transplantation: An analysis of the SPLIT database. Am J Transplant 2007; 7: 2165.
27. Bucuvalas JC, Alonso E. Long-term outcomes after liver transplantation in children. Curr Opin Organ Transplant 2008; 13: 247.
28. Bucuvalas JC, Alonso E, Magee JC, et al. Improving long-term outcomes after liver transplantation in children. Am J Transplant 2008; 8: 2506.
29. Magee JC, Krishnan SM, Benfield MR, et al. Pediatric transplantation in the United States, 1997-2006. Am J Transplant 2008; 8: 935.
30. Kamath BM, Olthoff KM. Liver Transplantation in Children: Update. Pediatr Clin N Am 2010; 57: 401
31. Wallot MA, Mathot M, Janssen M, et al. Long-term survival and late graft loss in pediatric liver transplant recipients-A 15-year singlecenter experience. Liver Transpl 2002; 8: 615.
32. Cox KL, Freese DK. Tacrolimus (FK506): The pros and cons of its use as an immunosuppressant in pediatric liver transplantation. Clin Invest Med 1996; 19: 389.
33. Molmenti EP, Nagata DE, Roden JS, et al. Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population. Am J Transpl 2001; 1: 356.
34. Jain AB, Nalesnik M, Reyes J, et al. Post-transplant lymphoproliferative disorders (PTLD) in liver transplantation (LTx): A twenty year experience. Ann Surg 2002; 236: 429.
35. Dhillon MS, Rai JK, Gunson BK, et al. Post-transplant lymphoproliferative disease in liver transplantation. Br J Radiol 2007; 80: 337.
36. Marino D, Burra P, Boccagni P, et al. Post-transplant lymphoproliferative disorders in liver transplanted patients: A single-centre experience. Anticancer Res 2010; 30: 2383.
37. Haagsma EB, Klompmaker IJ, Verwer R, et al. Long-term results after liver transplantation in adults. Scand J Gastroenterol 1991; 188: 38.
38. Jain AB, Yee LD, Nalesnik MA, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193.
39. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141.
40. Fung JJ, Jain AB, Kwak EJ, et al. De novo malignancies after liver transplantation: A major cause of late death. Liver Transpl 2001; 1: S109.
41. Sanchez EQ, Marubashi S, Jung G, et al. De novo tumors after liver transplantation: A single-institution experience. Liver Transpl 2002; 8: 285.
42. Jain A, Patil VP, Fung J. Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up. Liver Transpl 2008; 14: 1406.
43. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14.
44. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Cecka JM, Terasaki PI, eds. Clinical transplantation Los Angeles: UCLA Tissue Typing Laboratory 1994, p 99.
45. Jain AB, Mazariegos G, Kashyap R, et al. Pediatric liver transplantation: A single center experience spanning 20 years. Transplantation 2002; 73: 941.
46. Boillot O, Viale JP, Gratadour P, et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: A pilot study. Transplantation 1998; 66: 1182.
47. Jain AB, Demetris A, Kashyap R, et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001; 7: 623.
48. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: A meta-analysis. Am J Transplant 2006; 6: 1578.
49. Uemura T, Ikegami T, Sanchez EQ, et al. Late acute rejection after liver transplantation impacts patient survival. Clin Transplant 2008; 22: 316.
50. McCauley J. The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens 1993; 2: 662.
51. McDiarmid SV, Colonna JO II, Shaked A, et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. Transplantation 1993; 56: 847.
52. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58: 170.
53. McDiarmid SV, Ettenger RB, Fine RN, et al. Serial decrease in glomerular filtration rate in long-term pediatric liver transplantation survivors treated with cyclosporine. Transplantation 1989; 47: 314.
54. Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5: 1111.
55. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001; 72: 1934.
56. Gonwa TA. Treatment of renal dysfunction after orthotopic liver transplantation: Options and outcomes. Liver Transpl 2003; 9: 778.
57. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitorsparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
58. Jain A, Sharma R, Ryan C, et al. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction. Liver Transpl 2008; 14: 202.
59. Kamphues C, Bova R, Röcken C, et al. Safety of mycophenolate mofetil monotherapy in patients after liver transplantation. Ann Transplant 2009; 14: 40.
60. Pham PT, Pham PC, Wilkinson AH. Management of renal dysfunction in the liver transplant recipients. Curr Opin Organ Transplant 2009; 14: 231.
61. Karie-Guigues S, Janus N, Saliba F, et al. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): The TRY study. Liver Transpl 2009; 15: 1083.
62. Tsai MK, Wu FL, Lai IR, et al. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy. Int J Artif Organs 2009; 32: 371.
63. Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 2001; 7(11 suppl 1): S22.
64. Jain AB, Fung JJ, Todo S, et al. One thousand consecutive primary orthotopic liver transplants under FK 506: Survival and adverse events. Transplant Proc 1995; 27: 1099.
65. Jain AB, Reyes J, Kashyap R, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Longterm follow up of the first 1000 patients. Ann Surg 1999; 230: 441.
66. Jain A, Marcos A, Reyes J, et al. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. Transplant Proc 2005; 37: 1207.